Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laura O Hern

Physician Assistant Little Rock, AR Physician Assistant

NPI 1346556511 CMS profile 10523365

10001 Lile Dr, Little Rock, AR 72205

Open in the dashboard

General payments

$6,894

335 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura O Hern of Little Rock, AR is reported in the CMS Open Payments database as having received $6,894 across 335 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,989 91
2024 General $1,421 70
2023 General $1,368 92
2022 General $1,242 42
2021 General $874 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura O Hern
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Laura O Hern were reported at $1,989. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Laura O Hern Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $874 $132 $37–$438 $132
2022 $1,242 $155 $48–$522 $149
2023 $1,368 $167 $52–$557 $160
2024 $1,421 $178 $55–$600 $164
2025 $1,989 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $641 39 payments
  2. Sanofi-Aventis U.S. LLC $612 31 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $504 27 payments
  4. Insulet Corporation $445 15 payments
  5. Abbott Laboratories $427 17 payments
  6. Amgen Inc. $408 34 payments
  7. Dexcom, Inc. $389 43 payments
  8. CeQur Corporation $379 2 payments
  9. Novo Nordisk Inc $373 12 payments
  10. AbbVie, Inc. $326 14 payments
  11. Other $2,391 101 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,749 333 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $125 1 payment
  3. Education $20 1 payment
Products named General payments · program years 2021–2025
  1. Kerendia $504 27 payments
  2. Omnipod $445 15 payments
  3. CeQur Simplicity $379 2 payments
  4. Ozempic $358 11 payments
  5. MOUNJARO $326 16 payments
  6. Dexcom G6 Transmitter $310 39 payments
  7. Korlym $308 17 payments
  8. SYNTHROID $278 12 payments
  9. EVENITY $266 21 payments
  10. t:slim X2 Insulin Pump with Control-IQ $264 7 payments
  11. Other $4,604 226 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 83 drugs

Part D claims

3,873

Median for Physician Assistant: 241

Drug cost

$1,205,784

Median for Physician Assistant: $4,110

Branded share of claims

48.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 331 $344,845
Ozempic Semaglutide Brand 245 $266,570
Tresiba Flextouch U-200 Insulin Degludec Brand 114 $121,696
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 51 $77,568
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 62 $44,612
Tresiba Flextouch U-100 Insulin Degludec Brand 56 $35,404
Jardiance Empagliflozin Brand 30 $34,847
Farxiga Dapagliflozin Propanediol Brand 38 $26,351
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 26 $23,882
Fiasp Flextouch Insulin Aspart (Niacinamide) Brand 17 $20,963

The 10 drugs with the highest cost, of 83 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$75,058

Medicare's payments for the services billed

Medicare patients

270

Average age 72

Services billed

3,840

171 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 53%
Chronic kidney disease 44%
Ischemic heart disease 36%
Osteoporosis 26%
Depression 24%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
  • Corcept Therapeutics $148
$148 — —
JARDIANCE
  • Lilly USA, LLC $98
  • Boehringer Ingelheim Pharmaceuticals, Inc. $29
$127 30 —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $111
$111 — —
MOUNJARO
  • Lilly USA, LLC $89
$89 331 —
SYNTHROID
  • AbbVie, Inc. $62
$62 57 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

335 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record